NCT00699608View on ClinicalTrials.gov

An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.

PHASE3CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Healthy SubjectsSleep Initiation and Maintenance Disorders
Interventions
DRUG

GSK1755165; placebo; zopiclone

Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone

Trial Locations (1)

GU2 7XP

GSK Investigational Site, Guildford

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00699608 - An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers. | Biotech Hunter | Biotech Hunter